Harvard Pilgrim & Amgen Enter Into Value-Based Purchasing Arrangement For Cholesterol Drug Repatha

On May 2, 2017, Harvard Pilgrim Health Care (HPHC) and Amgen, Inc. (Amgen) announced that they had reached an agreement on a value-based purchasing agreement for the cholesterol drug Repatha. In the agreement, Amgen will refund the cost of the drug for any eligible consumer who experiences a resulting heart attack or stroke while on Repatha for six months or more while maintaining appropriate compliance on the drug.

Repatha is intended for individuals at high risk for cardiovascular diseases who are not able to adequately control their low-density lipoprotein (LDL-C) levels (bad cholesterol) through dietary changes and . . .